Castera_edit_Layout 1 28/09/2009 10:22 Page 47
Non-invasive Assessment of Disease Severity
1. Bravo AA, Sheth SG, Chopra S, Liver biopsy, N Engl J Med, 23. Sud A, Hui JM, Farrell GC, et al., Improved prediction of in patients with chronic hepatitis C, Hepatology,
2001;344(7):495–500. fibrosis in chronic hepatitis C using measures of insulin 2005;41(1):48–54.
2. Intraobserver and interobserver variations in liver resistance in a probability index, Hepatology, 44. Castera L, Vergniol J, Foucher J, et al., Prospective
biopsy interpretation in patients with chronic hepatitis 2004;39(5):1239–47. comparison of transient elastography, Fibrotest, APRI,
C. The French METAVIR Cooperative Study Group, 24. Islam S, Antonsson L, Westin J, Lagging M, Cirrhosis in and liver biopsy for the assessment of fibrosis in
Hepatology, 1994;20(1 Pt 1):15–20. hepatitis C virus-infected patients can be excluded chronic hepatitis C, Gastroenterology, 2005;128(2): 343–50.
3. Brunt EM, Janney CG, Di Bisceglie AM, et al., Non- using an index of standard biochemical serum markers, 45. Coco B, Oliveri F, Maina AM, et al., Transient
alcoholic steatohepatitis: a proposal for grading and Scand J Gastroenterol, 2005;40(7):867–72. elastography: a new surrogate marker of liver fibrosis
staging the histological lesions, Am J Gastroenterol, 1999; 25. Adams LA, Bulsara M, Rossi E, et al., Hepascore: an influenced by major changes of transaminases, J Viral
94(9):2467–74. accurate validated predictor of liver fibrosis in chronic Hepat, 2007;14(5):360–69.
4. Kleiner DE, Brunt EM, Van Natta M, et al., Design and hepatitis C infection, Clin Chem, 2005;51(10):1867–73. 46. Marcellin P, Ziol M, Bedossa P, et al., Non-invasive
validation of a histological scoring system for 26. Cales P, Oberti F, Michalak S, et al., A novel panel of assessment of liver fibrosis by stiffness measurement in
nonalcoholic fatty liver disease, Hepatology, 2005;41(6): blood markers to assess the degree of liver fibrosis, patients with chronic hepatitis B, Liver Int, 2009;
1313–21. Hepatology, 2005;42(6):1373–81. 29(2):242–7.
5. Strader DB, Wright T, Thomas DL, Seeff LB, Diagnosis, 27. Fontana RJ, Kleiner DE, Bilonick R, et al., Modeling 47. Friedrich-Rust M, Ong MF, Martens S, et al., Performance
management, and treatment of hepatitis C, Hepatology, hepatic fibrosis in African American and Caucasian of transient elastography for the staging of liver fibrosis:
2004;39(4):1147–71. American patients with chronic hepatitis C virus a meta-analysis, Gastroenterology, 2008; 134(4):960–74.
6. Cadranel JF, Rufat P, Degos F, Practices of liver biopsy in infection, Hepatology, 2006;44(4):925–35. 48. Foucher J, Castera L, Bernard PH, et al., Prevalence and
France: results of a prospective nationwide survey. For 28. Koda M, Matunaga Y, Kawakami M, et al., FibroIndex, a factors associated with failure of liver stiffness
the Group of Epidemiology of the French Association for practical index for predicting significant fibrosis in measurement using FibroScan in a prospective study of
the Study of the Liver (AFEF), Hepatology, patients with chronic hepatitis C, Hepatology, 2007; 2114 examinations, Eur J Gastroenterol Hepatol, 2006;
2000;32(3):477–81. 45(2):297–306. 18(4):411–12.
7. Castera L, Negre I, Samii K, Buffet C, Pain experienced 29. Zeng MD, Lu LG, Mao YM, et al., Prediction of significant 49. Sagir A, Erhardt A, Schmitt M, Transient elastography is
during percutaneous liver biopsy, Hepatology, 1999; fibrosis in HBeAg-positive patients with chronic unreliable for detection of cirrhosis in patients with
30(6):1529–30. hepatitis B by a noninvasive model, Hepatology, acute liver damage, Hepatology, 2007;47(2):592–5.
8. Piccinino F, Sagnelli E, Pasquale G, Giusti G, 2005;42(6):1437–45. 50. Arena U, Vizzutti F, Corti G, et al., Acute viral hepatitis
Complications following percutaneous liver biopsy. A 30. Hui AY, Chan HL, Wong VW, et al., Identification of increases liver stiffness values measured by transient
multicentre retrospective study on 68,276 biopsies, chronic hepatitis B patients without significant liver elastography, Hepatology, 2008;47(2):380–84.
J Hepatol, 1986;2(2):165–73. fibrosis by a simple noninvasive predictive model, 51. Talwalkar JA, Yin M, Fidler JL, et al., Magnetic resonance
9. Bedossa P, Dargère D, Paradis V, Sampling variability of Am J Gastroenterol, 2005;100(3):616–23. imaging of hepatic fibrosis: emerging clinical
liver fibrosis in chronic hepatitis C, Hepatology, 2003;38: 31. Kelleher TB, Mehta SH, Bhaskar R, et al., Prediction of applications, Hepatology, 2008;47(1):332–42.
1449–57. hepatic fibrosis in HIV/HCV co-infected patients using 52. Huwart L, Sempoux C, Vicaut E, et al., Magnetic
10. Regev A, Berho M, Jeffers LJ, et al., Sampling error and serum fibrosis markers: The SHASTA index, J Hepatol, resonance elastography for the noninvasive staging of
intraobserver variation in liver biopsy in patients with 2005;43(1):78–84. liver fibrosis, Gastroenterology, 2008;135(1):32–40.
chronic HCV infection, Am J Gastroenterol, 2002;97(10): 32. Sterling RK, Lissen E, Clumeck N, et al., Development of 53. Non-invasive methods for the evaluation of hepatic
2614–18. a simple noninvasive index to predict significant fibrosis fibrosis/cirrhosis, 2006 (available at: www.has-santefr).
11. Rousselet MC, Michalak S, Dupre F, et al., Sources of in patients with HIV/HCV coinfection, Hepatology, 54. Foucher J, Chanteloup E, Vergniol J, et al., Diagnosis of
variability in histological scoring of chronic viral 2006;43(6):1317–25. cirrhosis by transient elastography (FibroScan): a
hepatitis, Hepatology, 2005;41(2):257–64. 33. Angulo P, Hui JM, Marchesini G, et al., The NAFLD prospective study, Gut, 2006;55(3):403–8.
12. Ratziu V, Charlotte F, Heurtier A, et al., Sampling fibrosis score: a noninvasive system that identifies liver 55. Kazemi F, Kettaneh A, N’Kontchou G, et al., Liver
variability of liver biopsy in nonalcoholic fatty liver fibrosis in patients with NAFLD, Hepatology, 2007; stiffness measurement selects patients with cirrhosis at
disease, Gastroenterology, 2005;128(7):1898–1906. 45(4):846–54. risk of bearing large oesophageal varices, J Hepatol,
13. Castera L, Assessing liver fibrosis, Exp Rev Gastroenterol 34. Lackner C, Struber G, Liegl B, et al., Comparison and 2006;45(2):230–35.
Hepatol, 2008;2:541–52. validation of simple noninvasive tests for prediction of 56. Vizzutti F, Arena U, Romanelli RG, et al., Liver stiffness
14. Manning DS, Afdhal NH, Diagnosis and quantitation of fibrosis in chronic hepatitis C, Hepatology, 2005;41(6): measurement predicts severe portal hypertension in
fibrosis, Gastroenterology, 2008;134(6):1670–81. 1376–82. patients with HCV-related cirrhosis, Hepatology, 2007;
15. Pinzani M, Vizzutti F, Arena U, Marra F, Technology 35. Poynard T, Morra R, Halfon P, et al., Meta-analyses of 45(5):1290–97.
Insight: noninvasive assessment of liver fibrosis by Fibrotest diagnostic value in chronic liver disease, 57. Bureau C, Metivier S, Peron JM, et al., Transient
biochemical scores and elastography, Nat Clin Pract BMC Gastroenterol, 2007;7(1):40. elastography accurately predicts presence of significant
Gastroenterol Hepatol, 2008;5(2):95–106. 36. Leroy V, Hilleret MN, Sturm N, et al., Prospective portal hypertension in patients with chronic liver
16. Imbert-Bismut F, Ratziu V, Pieroni L, et al., Biochemical comparison of six non-invasive scores for the diagnosis disease, Aliment Pharmacol Ther, 2008;27(12):1261–8.
markers of liver fibrosis in patients with hepatitis C virus of liver fibrosis in chronic hepatitis C, 58. Castera L, Le Bail B, Roudot-Thoraval F, et al., Early
infection: a prospective study, Lancet, 2001; J Hepatol, 2007;46(5):775–82. detection in clinical practice of cirrhosis and
357(9262):1069–75. 37. Parkes J, Guha IN, Roderick P, Rosenberg W, oesophageal varices in chronic hepatitis C: comparison
17. Forns X, Ampurdanes S, Llovet JM, et al., Identification of Performance of serum marker panels for liver fibrosis in of transient elastography (FibroScan) with standard
chronic hepatitis C patients without hepatic fibrosis by a chronic hepatitis C, J Hepatol, 2006;44(3):462–74. laboratory tests and non invasive scores,
simple predictive model, Hepatology, 2002;36: 986–92. 38. Sebastiani G, Vario A, Guido M, et al., Stepwise J Hepatol, 2009;50:59–68.
18. Wai CT, Greenson JK, Fontana RJ, et al., A simple non- combination algorithms of non-invasive markers to 59. Carrion JA, Navasa M, Bosch J, et al., Transient
invasive index can predict both significant fibrosis and diagnose significant fibrosis in chronic hepatitis C, elastography for diagnosis of advanced fibrosis and
cirrhosis in patients with chronic hepatitis C, Hepatology, J Hepatol, 2006;44(4):686–93. portal hypertension in patients with hepatitis C
2003;38(2):518–26. 39. Sandrin L, Fourquet B, Hasquenoph JM, et al., Transient recurrence after liver transplantation, Liver Transpl,
19. Lok AS, Ghany MG, Goodman ZD, et al., Predicting elastography: a new noninvasive method for 2006;12(12):1791–8.
cirrhosis in patients with hepatitis C based on standard assessment of hepatic fibrosis, Ultrasound Med Biol, 60. Lemoine M, Katsahian S, Ziol M, et al. Liver stiffness
laboratory tests: results of the HALT-C cohort, Hepatology, 2003;29(12):1705–13. measurement as a predictive tool of clinically significant
2005;42(2):282–92. 40. Castera L, Forns X, Alberti A, Non-invasive evaluation of portal hypertension in patients with compensated HCV
20. Patel K, Gordon SC, Jacobson I, et al., Evaluation of a liver fibrosis using transient elastography, J Hepatol, or alcohol-related cirrhosis, Aliment Pharmacol Ther,
panel of non-invasive serum markers to differentiate 2008;48(5):835–47. 2008;28:1102–10.
mild from moderate-to-advanced liver fibrosis in chronic 41. Fraquelli M, Rigamonti C, Casazza G, et al., 61. Castera L, Denis J, Babany G, Roudot-Thoraval F. Evolving
hepatitis C patients, J Hepatol, 2004;41(6): 935–42. Reproducibility of transient elastography in the practices of non-invasive markers of liver fibrosis in
21. Leroy V, Monier F, Bottari S, et al., Circulating matrix evaluation of liver fibrosis in patients with chronic liver patients with chronic hepatitis C in France: Time for
metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 disease, Gut, 2007;56(7):968–73. new guidelines?, J Hepatol, 2007;46(3):528–9.
and TIMP-2 as serum markers of liver fibrosis in patients 42. Roulot D, Czernichow S, Le Clesiau H, et al., Liver 62. Sebastiani G, Alberti A, Non invasive fibrosis biomarkers
with chronic hepatitis C: comparison with PIIINP and stiffness values in apparently healthy subjects: Influence reduce but not substitute the need for liver biopsy, World
hyaluronic acid, Am J Gastroenterol, 2004; 99(2):271–9. of gender and metabolic syndrome, J Hepatol, J Gastroenterol, 2006;12(23):3682–94.
22. Rosenberg WM, Voelker M, Thiel R, et al., Serum markers 2008;48(4):606–13.
detect the presence of liver fibrosis: A cohort study, 43. Ziol M, Handra-Luca A, Kettaneh A, et al., Noninvasive
Gastroenterology, 2004;127(6):1704–13. assessment of liver fibrosis by measurement of stiffness
EUROPEAN GASTROENTEROLOGY & HEPATOLOGY REVIEW 47
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76